Cargando…
PD-1/PD-L1抑制剂联合治疗相关不良反应的研究进展
The development of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of cancer patients, but a large population of patients are still ineffective to ICIs treatment or develop aquired drug resistance. In order to improve the clinical benefits, a number of studies on ICIs ba...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317089/ https://www.ncbi.nlm.nih.gov/pubmed/34275517 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.26 |